That’s got­ta hurt. FDA turns thumbs down on Spec­trum’s 'break­through' pitch for can­cer drug pozi­o­tinib and shares tum­ble

Every­body loves a break­through ther­a­py drug des­ig­na­tion from the FDA. But woe be­tide the pub­lic biotech com­pa­ny that comes away from the BTD quest emp­ty …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.